or Try an Advanced Search...

    Technical Analysis for LEGN - Legend Biotech Corporation

    Grade Last Price % Change Price Change
    C 56.61 -4.28% -2.53
    LEGN closed down 4.28 percent on Friday, July 26, 2024, on 77 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: Aug 13
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical LEGN trend table...
    Date Alert Name Type % Chg
    200 DMA Support Bullish 0.00%
    Slingshot Bullish Bullish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Shooting Star Candlestick Bearish -4.28%
    Multiple of Ten Bearish Other -4.28%
    Wide Bands Range Expansion -4.28%
    Overbought Stochastic Strength -4.28%
    NR7 Range Contraction -5.13%
    Older End-of-Day Signals for LEGN ...

       Recent Intraday Alerts

    Alert Time
    200 DMA Support about 8 hours ago
    Down 5% about 9 hours ago
    Down 1 ATR about 9 hours ago
    Down 3% about 12 hours ago
    Down 2 % about 12 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    LEGN Chart by TradingView
    Basic chart:

    Profile

    Legend Biotech Corporation develops cell therapy solutions for cancer patients. The company was founded in 2014 and is based in Cayman Islands. The company operates as a subsidiary of Genscript Biotech Corporation.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Life Sciences Cell Therapy Genscript Biotech Tax Investigation

    Is LEGN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 26 Legend Biotech expects adj. loss of ~$102.2M in 1H24
    Jul 26 Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
    Jul 21 Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
    Jul 15 Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
    Jul 15 Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
    Jul 12 Legend Biotech surges amid takeover speculation (update)
    Jul 10 Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
    Jul 9 BMO sees BMRN, LEGN, SLN as attractive M&A targets
    Jul 2 Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
    Jul 2 J&J says Carvykti beat standard drugs in late-stage blood cancer trial
    See more LEGN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 76.21
    52 Week Low 38.6
    Average Volume 1,275,531
    200-Day Moving Average 55.94
    50-Day Moving Average 46.89
    20-Day Moving Average 52.38
    10-Day Moving Average 57.61
    Average True Range 2.65
    RSI (14) 64.03
    ADX 43.03
    +DI 29.90
    -DI 13.80
    Chandelier Exit (Long, 3 ATRs) 52.93
    Chandelier Exit (Short, 3 ATRs) 50.55
    Upper Bollinger Bands 63.85
    Lower Bollinger Band 40.92
    Percent B (%b) 0.68
    BandWidth 43.77
    MACD Line 3.78
    MACD Signal Line 3.32
    MACD Histogram 0.4609
    Fundamentals Value
    Market Cap 10.32 Billion
    Num Shares 182 Million
    EPS -2.96
    Price-to-Earnings (P/E) Ratio -19.13
    Price-to-Sales 47.00
    Price-to-Book 8.30
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 61.85
    Resistance 3 (R3) 62.21 60.81 60.98
    Resistance 2 (R2) 60.81 59.48 60.64 60.69
    Resistance 1 (R1) 58.71 58.65 58.02 58.36 60.40
    Pivot Point 57.32 57.32 56.97 57.14 57.32
    Support 1 (S1) 55.22 55.98 54.52 54.86 52.82
    Support 2 (S2) 53.82 55.16 53.65 52.53
    Support 3 (S3) 51.72 53.82 52.24
    Support 4 (S4) 51.37